(Q37756116)

22 August 2017

1 reference

title

Pharmacokinetic/pharmacodynamic profile of posaconazole (English)

1 reference

22 August 2017

1 reference

1 reference

3

Cornelius J Clancy

1 reference

22 August 2017

5

Hartmut Derendorf

1 reference

22 August 2017

Yanjun Li

1

1 reference

22 August 2017

Ursula Theuretzbacher

series ordinal

2

1 reference

22 August 2017

M Hong Nguyen

series ordinal

4

1 reference

22 August 2017

publication date

1 June 2010

1 reference

Clinical Pharmacokinetics

22 August 2017

published in

1 reference

22 August 2017

volume

49

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

379-396

1 reference

The search for new triazole antifungal agents

22 August 2017

cites work

1 reference

12 December 2020

In vitro antifungal susceptibilities of Trichosporon species.

1 reference

12 December 2020

Utility of mould susceptibility testing

1 reference

12 December 2020

Posaconazole as salvage therapy for zygomycosis

1 reference

12 December 2020

Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy

1 reference

12 December 2020

In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature

1 reference

12 December 2020

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

1 reference

12 December 2020

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

1 reference

12 December 2020

In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results

1 reference

12 December 2020

Update on antifungal drug resistance mechanisms of Aspergillus fumigatus

1 reference

12 December 2020

Antifungal therapy of murine Aspergillus terreus infection

1 reference

12 December 2020

Fusarium infections in immunocompromised patients

1 reference

12 December 2020

In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

1 reference

12 December 2020

Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection

1 reference

12 December 2020

Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo

1 reference

12 December 2020

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

1 reference

12 December 2020

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

1 reference

12 December 2020

In vitro and in vivo activities of posaconazole against Coccidioides immitis

1 reference

12 December 2020

Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole

1 reference

12 December 2020

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints

1 reference

12 December 2020

Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae

1 reference

12 December 2020

Posaconazole: SCH 56592.

1 reference

12 December 2020

Posaconazole: clinical pharmacology and potential for management of fungal infections

1 reference

12 December 2020

In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species

1 reference

12 December 2020

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

1 reference

12 December 2020

In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

1 reference

12 December 2020

Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model

1 reference

12 December 2020

Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis

1 reference

12 December 2020

Organism-dependent fungicidal activities of azoles

1 reference

12 December 2020

Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.

1 reference

12 December 2020

In vitro activities of four novel triazoles against Scedosporium spp

1 reference

12 December 2020

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi

1 reference

12 December 2020

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

1 reference

12 December 2020

Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

1 reference

12 December 2020

In vitro antifungal susceptibilities of five species of sporothrix

1 reference

12 December 2020

Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection

1 reference

12 December 2020

In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis

1 reference

12 December 2020

Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects

1 reference

12 December 2020

A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS

1 reference

12 December 2020

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

1 reference

12 December 2020

Pharmacokinetics/pharmacodynamics of echinocandins

1 reference

12 December 2020

Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant

1 reference

12 December 2020

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

1 reference

12 December 2020

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

1 reference

12 December 2020

A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.

1 reference

12 December 2020

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

1 reference

12 December 2020

Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism

1 reference

12 December 2020

Antifungal susceptibilities of the species of the Pseudallescheria boydii complex

1 reference

12 December 2020

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

1 reference

12 December 2020

Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy

1 reference

12 December 2020

Successful treatment of relapsing disseminated coccidioidomycosis with cutaneous involvement with posaconazole

1 reference

12 December 2020

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

1 reference

12 December 2020

Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods.

1 reference

12 December 2020

Posaconazole plasma concentrations in juvenile patients with invasive fungal infection

1 reference

12 December 2020

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

1 reference

12 December 2020

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays

1 reference

12 December 2020

Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders.

1 reference

12 December 2020

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

1 reference

12 December 2020

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

1 reference

12 December 2020

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

1 reference

12 December 2020

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

12 December 2020

In vitro activity of posaconazole against clinical isolates of dermatophytes

1 reference

12 December 2020

Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.

1 reference

12 December 2020

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model

1 reference

12 December 2020

Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

1 reference

12 December 2020

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

1 reference

12 December 2020

Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.

1 reference

12 December 2020

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

1 reference

12 December 2020

Has antifungal susceptibility testing come of age?

1 reference

12 December 2020

1 reference

12 December 2020

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

1 reference

12 December 2020

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

12 December 2020

Voriconazole: therapeutic review of a new azole antifungal

1 reference

12 December 2020

Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection

1 reference

12 December 2020

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

1 reference

12 December 2020

Human pharmacogenomic variations and their implications for antifungal efficacy

1 reference

12 December 2020

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

1 reference

12 December 2020

Refractory coccidioidomycosis treated with posaconazole

1 reference

12 December 2020

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

1 reference

12 December 2020

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

1 reference

12 December 2020

Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation

1 reference

12 December 2020

Treatment of murine fusariosis with SCH 56592

1 reference

12 December 2020

Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans

1 reference

12 December 2020

A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans

1 reference

12 December 2020

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic profile of voriconazole

1 reference

12 December 2020

Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl.

1 reference

12 December 2020

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model

1 reference

12 December 2020

Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment

1 reference

12 December 2020

Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation

1 reference

12 December 2020

Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

1 reference

12 December 2020

Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis

1 reference

12 December 2020

In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi

1 reference

12 December 2020

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo

1 reference

12 December 2020

Posaconazole concentrations in the central nervous system

1 reference

12 December 2020

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

1 reference

12 December 2020

Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital

1 reference

12 December 2020

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

1 reference

12 December 2020

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

1 reference

12 December 2020

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

1 reference

12 December 2020

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

1 reference

12 December 2020

Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study

1 reference

12 December 2020

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

1 reference

12 December 2020

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

1 reference

12 December 2020

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

1 reference

12 December 2020

Multi-azole resistance in Aspergillus fumigatus

1 reference

12 December 2020

International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

1 reference

12 December 2020

Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing

1 reference

12 December 2020

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

1 reference

12 December 2020

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

1 reference

12 December 2020

Identification of the Cytochrome P450 Enzymes Involved in theN-Oxidation of Voriconazole

1 reference

12 December 2020

Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

1 reference

12 December 2020

Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers

1 reference

12 December 2020

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

1 reference

12 December 2020

Clinical significance of azole antifungal drug cross-resistance in Candida glabrata

1 reference

12 December 2020

Disposition of posaconazole following single-dose oral administration in healthy subjects

1 reference

12 December 2020

SCH56592 treatment of murine invasive aspergillosis

1 reference

12 December 2020

Posaconazole: a broad-spectrum triazole antifungal

1 reference

12 December 2020

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

1 reference

12 December 2020

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

1 reference

12 December 2020

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

1 reference

12 December 2020

Posaconazole (Noxafil): a new triazole antifungal agent.

1 reference

12 December 2020

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

1 reference

12 December 2020

Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia

1 reference

12 December 2020

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

12 December 2020

In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing

1 reference

12 December 2020

Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease

1 reference

12 December 2020

10.2165/11319340-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1014546160

0 references

1 reference